<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343042</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-017</org_study_id>
    <nct_id>NCT02343042</nct_id>
  </id_info>
  <brief_title>Selinexor and Backbone Treatments of Multiple Myeloma Patients</brief_title>
  <acronym>STOMP</acronym>
  <official_title>A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will independently assess the efficacy and safety of 8 combination therapies in 9
      arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with
      relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The
      combinations to be evaluated are:

        -  Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

        -  Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete

        -  Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete

        -  Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd)

        -  Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete

        -  Arm 6: Selinexor + dexamethasone + carfilzomib (SKd)

        -  Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM

        -  Arm 8: Selinexor + dexamethasone + ixazomib (SNd)

        -  Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd)

      Selinexor pharmacokinetics:

        -  PK Run-in (Days 1-14):

      Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase
      (i.e., Arm 4 SPVd, Arm 6 SKd, Arm 8 SNd, Arm 9 SPEd) will also first be enrolled to a
      pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to
      evaluate the PK of selinexor before and after co-administration with a strong CYP3A4
      inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, clinical study with Dose Escalation (Phase 1) and
      Expansion (Phase 2) to independently assess the MTD, efficacy , and safety of 8 combination
      therapies in 9 arms in patients with RRMM and NDMM. Patients will be assigned to treatment
      arms based on their diagnoses and treatment histories. For 9 patients, a PK Run-in period
      will precede Cycle 1 (DLT evaluation) to assess selinexor PK when co-administered with a
      strong CYP3A4 inhibitor. In the Dose Escalation Phase (Phase 1): (a) in Arm 1 (SPd), Arm 2
      (SVd), and Arm 3 (SRd in RRMM), patients will be randomized to either QW or BIW selinexor
      dosing cohorts; (b) in Arm 5 (SDd), patients will be sequentially assigned in blocks of 3 to
      either QW or BIW selinexor dosing; (c) in Arm 4 (SPVd), Arm 6 (SKd), Arm 7 (Srd in NDMM), Arm
      8 (SNd), and Arm 9 (SPEd), patients will be assigned to QW selinexor dosing.

      Starting in protocol version 8.0, patients enrolled to the Dose Escalation Phase of Arm 4
      (SPVd), Arm 6 (SKd), Arm 8 (SNd), and Arm 9 (SPEd) will first be enrolled to a 14-day PK
      Run-in period (selinexor +/- clarithromycin) until 9 patients have been enrolled. During this
      14-day PK Run-in period, selinexor 40 mg will be administered alone on Day 1, clarithromycin
      500 mg twice daily (BID) will be administered on Days 2-8, and selinexor 40 mg will again be
      administered on Day 8 with the morning clarithromycin dose. Blood samples for PK analysis
      will be collected pre-dose and 1 (± 10 min), 1.5 (± 10 min), 2 (± 10 min), 3 (± 10 min), 4 (±
      10 min), 5 (± 10 min), 6 (± 10 min), 8 (± 10 min), and 24 h (± 30 min) hours after selinexor
      is dosed on Day 1 (without clarithromycin) and Day 8 (with clarithromycin). Patients will
      then proceed to the DLT evaluation period that will begin after the completion of the 14-day
      PK Run-in period; this day will be designated as Cycle 1 Day 1 (C1D1) in the Dose Escalation
      Phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation)</measure>
    <time_frame>12 months</time_frame>
    <description>Maximum tolerated dose (MTD) for once weekly (QW) and twice weekly (BIW) selinexor dose cohorts in the 9 Arms being evaluated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation)</measure>
    <time_frame>12 months</time_frame>
    <description>Recommended Phase-2 dose (RP2D) for each Arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation)</measure>
    <time_frame>14 days</time_frame>
    <description>Maximum plasma concentration (Cmax) of selinexor over a dosing interval when given with and without clarithromycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation)</measure>
    <time_frame>14 days</time_frame>
    <description>Total exposure of selinexor in the blood (AUC0-last) from the time of dosing to the last measurable concentration collected when given with and without clarithromycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall response rate (ORR) for each Arm independently. ORR to include stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR), according to the International Myeloma Working Group (IMWG) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion)</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of response (DOR) for each Arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical benefit rate (CBR), defined as ORR plus minimal response (MR) for each Arm</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">437</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is 28 days
Cohort 1.1: SEL 60/80/100 mg PO once weekly DEX 40 mg PO once weekly POM 2/3/4 mg PO Days 1-21
Cohort 1.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly POM 3/4 mg PO Days 1-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle is either 21 or 35 days (depending on bortezomib dosing schedule)
Cohort 2.1: SEL 60/80/100 mg PO once weekly DEX 40 mg PO once weekly BOR 1.3 mg/m² subcutaneous (SC) once weekly
Cohort 2.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly BOR 1.3 mg/m² subcutaneous (SC) once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Selinexor, Low-dose DEX, &amp; Lenalidomide (SRd) in RR MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is 28 days
Cohort 3.1: SEL 40/60/80/100 mg PO once weekly DEX 40 mg PO once weekly LEN 15/25 mg PO Days 1-21
Cohort 3.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly LEN 15/25 mg PO Days 1-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor &amp; Clarithromycin:
For the first 9 patients enrolled into this dose escalation arm
14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1
Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
Dose-escalation Phase:
All patients enrolled into this Arm
Each cycle is 28 days.
Cohort 4.1:
SEL 20/40/60 mg PO once weekly DEX 40 mg PO once weekly POM 2/4 mg PO Days 1-21 BOR 1.3 mg/m² subcutaneous (SC) once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is 28 days
Cohort 5.1:
SEL 80/100 mg PO once weekly DEX 40 mg once weekly (IV or PO) DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly Cycle 3-6: Every other week Cycle 6 and greater: Once a month
Cohort 5.2:
SEL: 60 mg PO twice weekly DEX: 40 mg weekly (IV or PO) DARA: 16 mg/kg IV infusion Cycle 1-2: Once. weekly Cycle 3-6: Every other week Cycle 6 and greater: Once a month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, &amp; Carfilzomib (SKd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor &amp; Clarithromycin:
For the first 9 patients enrolled into this dose escalation arm
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
Dose-Escalation Phase:
All patients enrolled into this Arm
Each cycle is 28 days
Cohort 6.1:
SEL 60/80/100 mg PO once weekly on days 1, 8, 15, and 22 DEX 40 mg IV or PO once weekly CAR 56 or 70 mg/m² IV infusion once weekly on days 1, 8, 15, and 22.
Cohort 6.2:
SEL 60/80/100 mg PO once weekly on day 1, 8, and 15. DEX 40 mg IV or PO once weekly CAR 56 or 70 mg/m² IV infusion once weekly on day 1, 8, and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7: Selinexor,Low-dose DEX &amp; Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is 28 days
Cohort 7.1:
SEL 40/60/80 mg PO once weekly DEX 40 mg PO once weekly LEN 25 mg PO Days 1-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, &amp; Ixazomib (SNd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor &amp; Clarithromycin:
For the first 9 patients enrolled into this dose escalation arm
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
Dose-Escalation Phase:
All patients enrolled into this Arm
Each cycle is 28 days
Cohort 8.1:
SEL 60/80/100 mg PO once weekly DEX 20 mg PO twice weekly IXA 3/4 mg PO Days once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor &amp; Clarithromycin:
For the first 9 patients enrolled into this dose escalation arm
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
Dose-Escalation Phase:
All patients enrolled into this Arm
Each cycle is 28 days
Cohort 9.1:
SEL 40/60/80 mg PO once weekly DEX 28/20 mg PO twice weekly POM 2/4 mg PO Days 1-21 ELO 10 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Tablets</description>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_label>3: Selinexor, Low-dose DEX, &amp; Lenalidomide (SRd) in RR MM</arm_group_label>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, &amp; Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>7: Selinexor,Low-dose DEX &amp; Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, &amp; Ixazomib (SNd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <other_name>KPT-330</other_name>
    <other_name>XPOVIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral tablets in a multi-dose vial</description>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_label>3: Selinexor, Low-dose DEX, &amp; Lenalidomide (SRd) in RR MM</arm_group_label>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, &amp; Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>7: Selinexor,Low-dose DEX &amp; Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, &amp; Ixazomib (SNd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <other_name>Decadron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>3: Selinexor, Low-dose DEX, &amp; Lenalidomide (SRd) in RR MM</arm_group_label>
    <arm_group_label>7: Selinexor,Low-dose DEX &amp; Lenalidomide (SRd) in NDMM</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <other_name>Pomalyst®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Subcutaneous Injection (single use vial)</description>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <other_name>Darzalex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, &amp; Carfilzomib (SKd)</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, &amp; Ixazomib (SNd)</arm_group_label>
    <other_name>Ninlaro®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <other_name>Empliciti®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, &amp; Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, &amp; Ixazomib (SNd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide &amp; Elotuzumab</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent in accordance with federal, local, and institutional
             guidelines.

          2. Age ≥ 18 years at the time of informed consent.

          3. Histologically confirmed diagnosis with measurable disease for relapsed/refractory
             myeloma.

          4. Symptomatic MM for NDMM needing therapy, based on IMWG guidelines.

          5. Patients must have measurable disease as defined by at least one of the following:

               1. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA
                  myeloma, by quantitative IgA

               2. Urinary M-protein excretion at least 200 mg/24 hours

               3. Serum FLC ≥ 100 mg/L, provided that FLC ratio is abnormal

               4. If SPEP is felt to be unreliable for routine M-protein measurement (e.g., for IgA
                  MM), then quantitative Ig levels by nephelometry or turbidometry are acceptable

          6. Any non-hematological toxicities (except for peripheral neuropathy as described in
             exclusion criterion #22) that patients had from treatments in previous clinical
             studies must have resolved to ≤ Grade 2 by Cycle 1 Day 1.

          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.

          8. Adequate hepatic function within 28 days prior to C1D1:

               -  For SPd, SRd, and SPEd: Total bilirubin &lt; 2x upper limit of normal (ULN) (except
                  patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who
                  must have a total bilirubin of ≤ 3x ULN) and both aspartate aminotransferase
                  (AST) and alanine aminotransferase (ALT) &lt; 2.5x ULN

               -  For SVd, SPVd, SDd, and SNd: Total bilirubin of &lt; 1.5x ULN (except patients with
                  Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total
                  bilirubin of ≤ 3x ULN) and both AST and ALT &lt; 2.0x ULN

               -  For SKd: Total bilirubin &lt; 2x ULN (except patients with Gilbert's syndrome
                  [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x
                  ULN) and both AST and ALT &lt; 3.0x ULN

          9. Adequate renal function within 28 days prior to C1D1. Estimated creatinine clearance
             (CrCl) calculated using the formula of Cockroft and Gault (1976):

               -  ≥ 20 mL/min for SVd, SDd, and SKd arms

               -  ≥ 30 mL/min for SNd arm

               -  ≥ 45 mL/min for SPd, SPVd, and SPEd arms

               -  &gt; 60 mL/min for SRd arm

         10. Adequate hematopoietic function within 28 days prior to C1D1: total white blood cell
             (WBC) count ≥ 1,500/mm³, ANC ≥ 1,000/mm³, hemoglobin (Hb) ≥ 8.0 g/dL, and platelet
             count ≥ 150,000/mm³.

         11. Female patients of childbearing potential must have a negative serum pregnancy test at
             Screening. Female patients of childbearing potential and fertile male patients who are
             sexually active with a female of childbearing potential must use highly effective
             methods of contraception throughout the study and for 1 week following the last dose
             of study treatment.

             SPd (Arm 1) Only:

         12. Relapsed and refractory MM with:

               1. Documented evidence of progressive disease (PD) after achieving at least stable
                  disease (SD) for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)

               2. ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60
                  days from the end of the most recent MM regimen (i.e., refractory MM)

               3. Previously undergone ≥ 2 cycles of lenalidomide and a PI (in separate therapeutic
                  regimens [not for maintenance] or in combination)

               4. In the expansion arm at RP2D, patients must not be pomalidomide refractory

             SVd (Arm 2) Only:

         13. Relapsed or refractory MM with:

               1. Documented evidence of relapse after ≥ 1 previous line of therapy

               2. Not refractory to bortezomib in their most recent line of therapy

             SRd in RRMM (Arm 3) Only:

         14. Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as
             long as patient's MM was not refractory to prior lenalidomide; patients whose MM was
             refractory to lenalidomide maintenance regimens will be allowed in this cohort).

             SPVd (Arm 4) Only:

         15. Patients who received 1- 3 prior lines of therapy, including ≥ 2 cycles of
             lenalidomide and have demonstrated disease progression on their last therapy (may
             include prior bortezomib, as long as the patient's MM was not refractory to bortezomib
             therapy), but patients must be pomalidomide-naïve in the Dose Expansion at RP2D
             (Cohort 4.3 ONLY).

             SDd (Arm 5) Only:

         16. Patients who received ≥ 3 prior lines of therapy, including a PI and an IMiD, or
             patients with MM refractory to both a PI and an IMiD.

         17. Patients must not have received prior anti-CD38 monoclonal antibodies (Cohort 5.3 ONLY
             - Dose Expansion at RP2D).

             SKd (Arm 6) Only:

         18. Patients may have received prior PIs; however, their MM must NOT be refractory to
             carfilzomib.

             SRd in NDMM (Arm 7) Only:

         19. Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria
             or myeloma-defining events and need systemic therapy. No prior systemic therapy for
             NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg) or
             corticosteroid equivalent.

             SNd (Arm 8) Only:

         20. Patients must have MM that relapsed after 1 - 3 prior lines of therapy (may not
             include those with MM refractory to bortezomib or carfilzomib and patients must be
             ixazomib-naïve).

             SPEd (Arm 9) Only:

         21. Patients who received ≥ 2 prior therapies, including lenalidomide and a PI (in
             separate or the same regimens), but patients must be pomalidomide-naïve and
             elotuzumab-naïve in the Dose Expansion at RP2D (Cohort 9.3 ONLY).

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not eligible to enroll in this
        study:

          1. Smoldering MM

          2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and
             quantitative immunoglobulin levels cannot be used instead

          3. Documented active systemic amyloid light chain amyloidosis

          4. Active plasma cell leukemia

          5. Red Blood Cell (RBC) and platelet transfusions and blood growth factors within 14 days
             of C1D1.

          6. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks
             prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on
             long-term glucocorticoids during Screening do not require a washout period. Prior
             radiation is permitted for treatment of fractures or to prevent fractures as well as
             for pain management

          7. Patients with history of SCC with residual paraplegia (Dose Escalation Phase only).

          8. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1

          9. Prior autologous stem cell transplantation &lt; 1 month, or allogeneic stem cell
             transplantation &lt; 3 months prior to C1D1

         10. Active graft versus host disease after allogeneic stem cell transplantation

         11. Life expectancy &lt; 3 months

         12. Major surgery within 4 weeks prior to C1D1

         13. Active, unstable cardiovascular function:

               1. Symptomatic ischemia, or

               2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with
                  ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree
                  atrioventricular (AV) block or asymptomatic left anterior fascicular block/right
                  bundle branch block (LAFB/RBBB) will not be excluded), or

               3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or

               4. Myocardial infarction (MI) within 3 months prior to C1D1

               5. Ejection fraction (EF) &lt; 50% at Screening

         14. Uncontrolled active hypertension

         15. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals within one week prior to first dose

         16. Known active hepatitis A, B or C

         17. Known HIV infection or HIV seropositivity

         18. Any active gastrointestinal dysfunction that prevents the patient from swallowing
             tablets or interferes with absorption of study treatment

         19. Currently pregnant or breastfeeding

         20. A serious psychiatric or medical condition which, in the opinion of the Investigator,
             could interfere with treatment

         21. Hypersensitivity to any of the treatments for the Arm in which the patient is enrolled

         22. Prior exposure to a SINE compound, including selinexor

             In the SVd Arm (Arm 2), SPVd (Arm 4), and SNd Arm (Arm 8) only:

         23. Prior history of neuropathy Grade &gt; 2, or Grade ≥ 2 neuropathy with pain at screening
             (within 28 days prior to C1D1).

             Patients who are eligible for the selinexor PK Run-in only:

         24. Treatment with moderate or strong inhibitors/inducers of CYP3A within 7 days prior to
             Day 1 of the PK Run-in period

         25. Not able to receive a strong CYP3A4 inhibitor due to concomitant medications

             SKd Arm only:

         26. HBs Ag + plus HBc Ab + even though no active HBV hepatitis. If HBs Ag - plus HBc Ab +,
             treating physician needs to contact the medical monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>SShacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jonnsson Comprehensive Cancer Center / University of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>0095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <phone>888-798-0719</phone>
      <email>GSchiller@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhamed Baljevic, MD</last_name>
      <email>muhamed.baljevic@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Muhamed Baljevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noa Biran, MD</last_name>
      <phone>551-996-8704</phone>
      <email>Noa.Biran@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Noa Biran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <phone>212-305-5065</phone>
      <email>CTOInformation@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine / NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Rossi, MD</last_name>
      <email>adr9009@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Adriana Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilmot Cancer Center/ University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brea Lipe, MD</last_name>
      <email>Brea_Lipe@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Brea Lipe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha Alexander Tuchman, MD, MHS</last_name>
      <phone>984-974-0000</phone>
      <email>sascha_tuchman@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Sascha Alexander Tuchman, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Institute of Cancer/ Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
      <phone>919-668-1017</phone>
      <email>gaspa001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Callander, MD</last_name>
      <phone>608-265-8554</phone>
      <email>nsc@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Natalie Callander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center/Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar Bahlis, MD</last_name>
      <phone>+1 (403) 944-1880</phone>
      <email>nbahlis@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Nizar Bahlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute / University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Venner</last_name>
      <phone>780-432-8771</phone>
    </contact>
    <investigator>
      <last_name>Chris Venner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver,</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrell White</last_name>
    </contact>
    <investigator>
      <last_name>Darrell White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Dean</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>5241</phone_ext>
    </contact>
    <investigator>
      <last_name>Christine Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital / McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selinexor</keyword>
  <keyword>KCP-330</keyword>
  <keyword>STOMP</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Ixazomib</keyword>
  <keyword>Elotuzumab</keyword>
  <keyword>Clarithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

